Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | NCT03080974 | Trialant

RecruitingInterventionalPhase 2Updated Oct 29, 2025

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Overview

Key facts that identify this study and show where it stands today.

What the study is about and why it is being run, in the researchers' own words.

Official Title: Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Brief Summary: Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Detailed Description: Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively.

The medical conditions and diseases this study investigates.

The treatments and procedures being evaluated in this study.

Who can join this study and the criteria used to decide.

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Eligibility Criteria: Inclusion Criteria:

≥ 18 years if age

Diagnosed with stage III pancreatic cancer

Tumor is measurable

Glomerular Filtration Rate > 60 m/L/min/1.73 m(2)

Willing and able to comply with the protocol requirements

Able to comprehend and have signed the informed consent to participate

Exclusion Criteria:

Participating in another clinical trial for the treatment of cancer at time of screening

Are pregnant or currently breast feeding

Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure

Have non-removable implants with metal parts within 1 cm of the target lesion

Had a myocardial infarction within 3 months prior to enrollment

How the study is designed and how its participant groups are organized.

The people to reach with questions about this study or how to join it.

Robert Martin, MD, PhDContact

robert.martin@louisville.edu502-629-3355

Where the study is run and whether each site is currently recruiting.

University of LouisvilleRecruiting

Louisville, Kentucky 40202, United States

The organizations and people involved in this study.

Other registered studies that closely resemble this one.